{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:03:42Z","timestamp":1792789422287,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.beha.2011.12.001","type":"journal-article","created":{"date-parts":[[2012,2,5]],"date-time":"2012-02-05T05:54:44Z","timestamp":1328421284000},"page":"119-130","source":"Crossref","is-referenced-by-count":52,"title":["Primary CNS lymphoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Andr\u00e9s J.M.","family":"Ferreri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerenziana","family":"Marturano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.beha.2011.12.001_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/10428190802311441","article-title":"Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment","volume":"49","author":"Rubenstein","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.beha.2011.12.001_bib2","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1200\/JCO.2003.01.135","article-title":"Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, Lugano, Switzerland, June 12 to 15, 2002","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2011.12.001_bib3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","article-title":"A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases","volume":"107","author":"Camilleri-Broet","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2011.12.001_bib4","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0002-9440(10)65526-5","article-title":"Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4\u201334 gene segment","volume":"155","author":"Montesinos-Rongen","year":"1999","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.beha.2011.12.001_bib5","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnen\/61.10.926","article-title":"Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system","volume":"61","author":"Montesinos-Rongen","year":"2002","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"10.1016\/j.beha.2011.12.001_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.jnen.0000248553.45456.96","article-title":"Transcriptional profiling of the nuclear factorkappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression","volume":"66","author":"Courts","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"10.1016\/j.beha.2011.12.001_bib7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00401-010-0709-7","article-title":"Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma","volume":"120","author":"Montesinos-Rongen","year":"2010","journal-title":"Acta Neuropathol"},{"issue":"9","key":"10.1016\/j.beha.2011.12.001_bib8","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2005-03-0897","article-title":"Gene expression and angiotropism in primary CNS lymphoma","volume":"107","author":"Rubenstein","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2011.12.001_bib9","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.leu.2405019","article-title":"Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell","volume":"22","author":"Montesinos-Rongen","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2011.12.001_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/path.2399","article-title":"Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immuneprivileged sites: the importance of apoptosis and immunomodulatory pathways","volume":"216","author":"Booman","year":"2008","journal-title":"J Pathol"},{"issue":"5","key":"10.1016\/j.beha.2011.12.001_bib11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2141.2004.05109.x","article-title":"Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas","volume":"126","author":"Ferreri","year":"2004","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2011.12.001_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11060-009-0032-0","article-title":"Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status","volume":"97","author":"Kurzwelly","year":"2010","journal-title":"J Neurooncol"},{"issue":"10","key":"10.1016\/j.beha.2011.12.001_bib13","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1212\/WNL.58.10.1513","article-title":"A multicenter study of treatment of primary CNS lymphoma","volume":"58","author":"Ferreri","year":"2002","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.beha.2011.12.001_bib14","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2011.12.001_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11060-004-3390-7","article-title":"Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients","volume":"72","author":"Kuker","year":"2005","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.beha.2011.12.001_bib16","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/WNL.59.5.762","article-title":"Is a \u201cvanishing tumor\u201d always a lymphoma?","volume":"59","author":"Bromberg","year":"2002","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.beha.2011.12.001_bib17","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ana.21366","article-title":"Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma","volume":"63","author":"Porter","year":"2008","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.beha.2011.12.001_bib18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/(SICI)1097-0142(19960301)77:5<827::AID-CNCR4>3.0.CO;2-B","article-title":"Importance of complete staging in non hodgkin\u2019s lymphoma presenting as a cerebral mass lesion","volume":"77","author":"Ferreri","year":"1996","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.beha.2011.12.001_bib19","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1212\/01.wnl.0000326958.52546.f5","article-title":"Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients","volume":"71","author":"Fischer","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.beha.2011.12.001_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1215\/15228517-2007-061","article-title":"The utility of body FDG PET in staging primary central nervous system lymphoma","volume":"10","author":"Mohile","year":"2008","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.beha.2011.12.001_bib21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2011.12.001_bib22","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/1097-0142(20000915)89:6<1359::AID-CNCR21>3.0.CO;2-9","article-title":"A medical research council randomized trial in patients with primary cerebral nonhodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy","volume":"89","author":"Mead","year":"2000","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.beha.2011.12.001_bib23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF00177277","article-title":"Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD)","volume":"30","author":"Glass","year":"1996","journal-title":"J Neurooncol"},{"issue":"2","key":"10.1016\/j.beha.2011.12.001_bib24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0360-3016(01)01639-X","article-title":"Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate","volume":"51","author":"Reni","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.beha.2011.12.001_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/08880018809031261","article-title":"Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction","volume":"5","author":"Lippens","year":"1988","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.beha.2011.12.001_bib26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bjc.6601472","article-title":"Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas","volume":"90","author":"Ferreri","year":"2004","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.beha.2011.12.001_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s002800000118","article-title":"Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis","volume":"46","author":"Tetef","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9700","key":"10.1016\/j.beha.2011.12.001_bib28","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beha.2011.12.001_bib29","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1634\/theoncologist.2010-0361","article-title":"Clinical relevance of the dose of cytarabine in the upfront treatment of primary cns lymphomas with methotrexate-cytarabine combination","volume":"16","author":"Ferreri","year":"2011","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.beha.2011.12.001_bib30","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.bjc.6603660","article-title":"Temozolomide as salvage treatment in primary brain lymphomas","volume":"96","author":"Reni","year":"2007","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.beha.2011.12.001_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11060-007-9397-0","article-title":"Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly","volume":"85","author":"Omuro","year":"2007","journal-title":"J Neurooncol"},{"issue":"7","key":"10.1016\/j.beha.2011.12.001_bib32","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdl070","article-title":"Prospective trial on topotecan salvage therapy in primary CNS lymphoma","volume":"17","author":"Fischer","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2011.12.001_bib33","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1212\/01.wnl.0000210464.94122.e1","article-title":"MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas","volume":"66","author":"Ferreri","year":"2006","journal-title":"Neurology"},{"issue":"suppl","key":"10.1016\/j.beha.2011.12.001_bib34","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1200\/jco.2008.26.15_suppl.2043","article-title":"Rituximab monotherapy for relapsed or refractory primary central nervous system lymphoma [abstract]","volume":"26","author":"Batchelor","year":"2008","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.beha.2011.12.001_bib35","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","article-title":"Combined immunochemotherapy with reduced whole brain radiotherapy for newly diagnosed primary CNS lymphoma","volume":"25","author":"Shah","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.12.001_bib36","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/cncr.23077","article-title":"Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma","volume":"110","author":"Iwamoto","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.beha.2011.12.001_bib37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1215\/15228517-2008-108","article-title":"First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (zevalin) in primary CNS lymphoma","volume":"11","author":"Maza","year":"2009","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.12.001_bib38","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","article-title":"Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma","volume":"25","author":"Rubenstein","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2011.12.001_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1016077907952","article-title":"Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?","volume":"58","author":"Khan","year":"2002","journal-title":"J Neurooncol"},{"issue":"2","key":"10.1016\/j.beha.2011.12.001_bib40","first-page":"711","article-title":"High-dose methotrexate for intraocular lymphoma","volume":"9","author":"Batchelor","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.beha.2011.12.001_bib41","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/annonc\/mdf080","article-title":"Relevance of intraocular involvement in the management of primary central nervous system lymphomas","volume":"13","author":"Ferreri","year":"2002","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.beha.2011.12.001_bib42","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S0161-6420(02)01125-9","article-title":"Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement","volume":"109","author":"Smith","year":"2002","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.beha.2011.12.001_bib43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/bjo.2007.127928","article-title":"Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience","volume":"92","author":"Frenkel","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.beha.2011.12.001_bib44","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/IAE.0b013e318192f574","article-title":"Rituximab for intraocular lymphoma","volume":"29","author":"Itty","year":"2009","journal-title":"Retina"},{"issue":"21","key":"10.1016\/j.beha.2011.12.001_bib45","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2008.19.3789","article-title":"Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience","volume":"27","author":"Angelov","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.beha.2011.12.001_bib46","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Radiation therapy oncology group study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2011.12.001_bib47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1023\/A:1006206602918","article-title":"Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL)","volume":"43","author":"Nelson","year":"1999","journal-title":"J Neurooncol"},{"issue":"2","key":"10.1016\/j.beha.2011.12.001_bib48","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(11)70018-3","article-title":"Wholebrain radiotherapy in primary CNS lymphoma","volume":"12","author":"Ferreri","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.beha.2011.12.001_bib49","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2010.01.066","article-title":"Consolidation radiotherapy in primary CNS lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy","volume":"80","author":"Ferreri","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.beha.2011.12.001_bib50","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ana.20804","article-title":"International study on low-grade primary central nervous system lymphoma","volume":"59","author":"Jahnke","year":"2006","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.beha.2011.12.001_bib51","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00041327-200312000-00006","article-title":"Solitary intracranial extra-osseous plasmacytoma presenting with ophthalmic signs","volume":"23","author":"Brannan","year":"2003","journal-title":"J Neuroophthalmol"},{"issue":"5","key":"10.1016\/j.beha.2011.12.001_bib52","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2008-04-151563","article-title":"CNS hodgkin lymphoma","volume":"112","author":"Gerstner","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2011.12.001_bib53","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1998.16.3.859","article-title":"Long-term survival in primary CNS lymphoma","volume":"16","author":"Abrey","year":"1998","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2011.12.001_bib54","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/annonc\/mdl464","article-title":"Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines","volume":"18","author":"Correa","year":"2007","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.12.001_bib55","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.12.001_bib56","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(10)70234-5","article-title":"How important is whole brain radiotherapy for treatment of primary CNS lymphoma?","volume":"11","author":"Cabanillas","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2011.12.001_bib57","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1200\/JCO.2001.19.3.742","article-title":"Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma","volume":"19","author":"Soussain","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.12.001_bib58","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2007.13.5533","article-title":"Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire","volume":"26","author":"Soussain","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.12.001_bib59","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1600-0609.2005.00508.x","article-title":"First-line autologous stem cell transplantation in primary CNS lymphoma","volume":"75","author":"Brevet","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2011.12.001_bib60","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bmt.1705452","article-title":"High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group","volume":"38","author":"Colombat","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2011.12.001_bib61","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","article-title":"High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma","volume":"24","author":"Illerhaus","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.12.001_bib62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3324\/haematol.11771","article-title":"High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system","volume":"93","author":"Illerhaus","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2011.12.001_bib63","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/annonc\/mdl458","volume":"18","author":"Montemurro","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2011.12.001_bib64","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/sj.bmt.1703917","article-title":"High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma","volume":"31","author":"Cheng","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2011.12.001_bib65","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2003.05.024","article-title":"Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis","volume":"21","author":"Abrey","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.12.001_bib66","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1080\/10428190802381238","article-title":"High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions","volume":"49","author":"Ferreri","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.beha.2011.12.001_bib67","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/annonc\/mdi075","article-title":"High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma","volume":"16","author":"Jahnke","year":"2005","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.beha.2011.12.001_bib68","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/neuonc\/2.1.40","article-title":"High-dose methotrexate for primary CNS lymphoma in 2 the elderly","volume":"2","author":"Ng","year":"2000","journal-title":"Neuro-Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.12.001_bib69","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1212\/01.wnl.0000276986.19602.c1","article-title":"Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma","volume":"69","author":"Hottinger","year":"2007","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.beha.2011.12.001_bib70","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1200\/JCO.2005.01.161","article-title":"Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma","volume":"23","author":"Nguyen","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611001101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611001101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T10:22:43Z","timestamp":1543227763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692611001101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1521692611001101"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2011.12.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}